02192 MEDLIVE
- 8.390
- +0.070+0.84%
MEDLIVE News
Hong Kong Stock Connect is on “vacation”. Who is violently boosting Hong Kong stocks?
On May 2, against the backdrop of the suspension of A-share funds and Hong Kong Stock Connect, the Hong Kong Stock Technology Index soared by more than 4%.
Medlive Technology More Than Doubles Profit in 2023
Medlive Technology (HKG:2192) recorded a 107% rise in attributable profit for the year ended Dec. 31, 2023, to 242.3 million yuan from 117.3 million yuan in 2022, according to the company's annual rep
醫脈通：年報2023
What logic? A-share fund managers bought Hong Kong stocks and only dared to take a heavy stock of pharmaceuticals...
MEDLIVE To Go Ex-Dividend On May 28th, 2024 With 0.1375 HKD Dividend Per Share
March 26th - $MEDLIVE(02192.HK)$ is trading ex-dividend on May 28th, 2024. Shareholders of record on May 29th, 2024 will receive 0.1375 HKD dividend per share on June 24th, 2024. The ex-dividend d
Selected announcements | CNPC's net profit last year exceeded 160 billion yuan; Pharmaceutical Federation's annual profit increased by more than 80% year-on-year
China Overseas Hongyang Group: Net profit of 2023 was 2.02 billion yuan, down 26.94% year on year; Zero Sports Auto: 2023 revenue of 16.747 billion yuan, up 35.22% year on year; Tencent Holdings: spent HK$1,001 billion to buy back 3.47 million shares on March 25.
Medical Pulse (02192) will pay a final dividend of $0.1248 per share on June 24
Medical Pulse (02192) announced that the company will distribute it on June 24, 2024 until 2024 until 2023...
Yimaitong (02192.HK)'s annual adjusted net profit of about 271 million yuan increased by about 86.8% year-on-year
Gelonghui (02192.HK) announced on March 25, that for the year ended December 31, 2023, the Group's revenue was approximately RMB 412.0 million, an increase of 31.2% over the same period last year. While expanding revenue, the Group continued to increase its profitability. The Group's net profit increased from RMB 126.4 million for the year ended December 31, 2022 to RMB 251.8 million for the year ended December 31, 2023, an increase of 99.1% over the previous year. Net profit margin increased by approximately 40.3% for the year ended December 31, 2022
MEDLIVE: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Medical Communications (02192.HK) plans to hold a board meeting on March 25 to approve the annual results
Gelonghui March 13 | Medical Communications (02192.HK) announced that the company will hold a board meeting on March 25, 2024 (Monday) to consider and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to consider paying a final dividend (if any).
MEDLIVE: DATE OF BOARD MEETING
Selected announcements: Xiaopeng Motor signs joint development agreement with Volkswagen, etc.; Baidu Q4 adjusted net profit increased 44% year-on-year
Xinyi Solar Energy: Annual net profit increased 9.6% to HK$4.187.1 billion, with final interest of HK15 cents per share; Xinyi Glass: Profit attributable to equity holders increased 4.6% to HK$5.365 billion in 2023, with a final interest rate of HK37.0 cents.
Medlive Technology to Double Profit in 2023
Medlive Technology (HKG:2192) expects its attributable profit for the year ended Dec. 31, 2023, to rise to at least 235 million yuan from 117.3 million yuan a year earlier, the online physician platfo
Medical Pulse (02192.HK) Yingxi: Net profit due to mother is expected to increase to no less than 235 million yuan in fiscal year 2023
On February 28, GLONGHUI (02192.HK) announced that for the year ended December 31, 2023 (“Fiscal Year 2023"), the board of directors expects revenue for fiscal year 2023 to increase from RMB 314 million to no less than RMB 410 million for the year ended December 31, 2022; profit attributable to owners of parent companies recorded a significant increase, increasing to no less than RMB 235 million from the profit attributable to owners of parent companies for the year ended December 31, 2022.
MEDLIVE: POSITIVE PROFIT ALERT
Medical Communications (02192.HK) received 43,000 additional shares of common stock from Fidelity International, worth approximately HK$265,300
On February 14, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on February 14, Pandanus Associates Inc. (Pandanus Associates Inc.) increased its shares of $43,000 in common shares at an average price of HK$6.1,697 per share on February 7, worth approximately HK$265,300. After the increase in holdings, the latest number of shares held by Fidelity International was 65.4569 million shares, and the good position ratio increased from 8.99% to 9.00%. This transaction involves other related parties: FIL Limited and Pandanus Partners
Yimaitong (02192) cancelled the repurchased shares of 100,000 shares on December 20
Yimaitong (02192) issued an announcement to cancel the repurchased shares of 100,000 shares on December 20, 2023.
Fidelity International sold 1,245,500 common shares of Medical Connect (02192.HK), worth approximately HK$10.275,400
According to reports on November 20, according to documents disclosed by the Hong Kong Stock Exchange on November 20, Fidelity International (FIL Limited) sold $1,245,500 common shares of $02192.HK (02192.HK) on November 15 at an average price of HK$8.25 per share, worth about HK$10.275,400. After the sale, the latest number of shares held by Fidelity International was 64,912,900 shares, and the good position ratio fell from 9.10% to 8.93%. This transaction involves other related parties: Pandanus Associates Inc. and Pandanus
October 19 repurchase collection | AIA, Kuaishou-W, etc. have repurchased one after another, of which AIA spent HK$135 million
According to documents disclosed by HKEx on October 20, $AIA (01299.HK) $ and $Kuaishou-W (01024.HK) $ have repurchased shares. ① $AIA (01299.HK) $ repurchased 200,000 common shares on October 19, involving an amount of HK$135 million. The repurchase price per share ranged from HK$68.2 to HK$66.6. The cumulative number of securities repurchased so far this year (since the adoption of the ordinary resolution) was 148 million shares, accounting for 1.272% of the number of shares issued at the time the ordinary resolution was passed. ② $ Kuaishou-W (
Medlive to Buy 60% of Chinese Pharma Consulting Firm for Some 34 Million Yuan
Medlive Technology (HKG:2192) said subsidiary Kingyee (Beijing) will acquire a 60% stake in Linberg Consulting & Intelligence (Shanghai), from three sellers, for about 33.93 million yuan. The deal giv
Analysis
Price Target
No Data
